News_2006_email.indd page 1
author: hill08
Cetuximab - [Medication] - Quest Diagnostics Patient Health Library Cetuximab Examples Brand Name Chemical Name Erbitux cetuximab How It Works Cetuximab belongs to a group of drugs known as monoclonal antibodies.Cetuximab - [Medication] - Quest Diagnostics Patient Health Library Cetuximab ...
Results -- View - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Results -- View - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
3rdWorld 6% for Not yet met; compiling cytarabine meningitis cytarabine unencapsulated and analyzing the liposomal Phase IV data Doxil Metastatic ovarian 6/ 28/ 99 Sequus (now J& J) Response rate (study 1): 22.2% Met doxorubicin carcinoma Response rate (study 2): 17.1% liposomal Response rate (study 3): 0% Doxil AIDS- related Kaposi's 11/ 17/ 95 Sequus (now J& J) PR (34 evaluable patients for...
author: tracy
subject: 3rdWorld
3rdWorld page 8
author: tracy
subject: 3rdWorld
BIOPHARMA FDA Approvals - - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
Innovative Agents in Lung and Colorectal Cancer - Another Step Nearer the Revolution One such class of innovative agents is the epidermal growth factor receptor (EGFR) inhibitor class, which is being investigated for NSCLC and colorectal cancer.- Scope Overview of EGFR inhibitors and their role in the NSCLC market- Strategy for maximizing the potential of EGFR inhibitors such as Iressa, Tarceva and Erbitux Report Highlights ImClone/BMS/Merck KGaA’s ...
author: BioPortfolio - Knowledge Management, Market Analysis and Market Research
Preview of the American Society of Clinical Oncology 40th Annual Meeting - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - Thomson Scientific : Meeting Previews : 2004 : Preview of the American Society of Clinical Oncology 40th Annual Meeting PREVIEW OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 40TH ANNUAL MEETING Date: 5-8 June 2004 Location: New Orleans, LA, USA Coverage The American Society of Clinical Oncology (ASCO) will celebrate...
Preview of the American Society of Clinical Oncology 41st Annual Meeting - Thomson Scientific Thomson.com - - - - - Advanced Search - - - EN : JP : CN : KR -- - - Thomson Scientific : Meeting Previews : 2005 : Preview of the American Society of Clinical Oncology 41st Annual Meeting PREVIEW OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 41ST ANNUAL MEETING Date: 13-17 May 2005 Location: Orlando, FL, USA Coverage The American Society of Clinical Oncology (ASCO) will hold its 41st...
BioPortfolio Limited Monoclonal Antibody Therapeutics - Current Market Dynamics & Future Outlook - 1.------ Executive Briefing - 2.------ Introduction - 2.1 --- Definition & Scope - 2.2---- Currently Marketed Monoclonal Antibody Therapeutics - 3.------ Market Size & Growth Rates - 3.1---- Global Market for Monoclonal Antibody Therapeutics - 3.2---- North American Market for Monoclonal Antibody...
The Cancer Market Outlook to 2009 Sept 2004 268 pages Table of Contents The Cancer Market Outlook to 2009 Executive Summary 12 Patient potential 12 Global market analysis 13 Leading players in the cancer market 14 Development of key cancer markets to 2009 15 Chapter 1 Patient potential 19 Summary 19 Introduction 21 Lung cancer 22 Disease description 22 Epidemiology 23 Current treatments 24 NSCLC 24 SCLC 25 Malignant...
BioPortfolio Limited TABLE OF CONTENTS Key findings 6 CHAPTER 1 INTRODUCTION 8 Epidemiology 9 Risk factors 10 Symptoms 12 Diagnosis 13 CHAPTER 2 TREATMENT AND PROGNOSIS BY STAGE 14 Staging and grading 14 Staging 14 Grading 15 Treatment and prognosis by stage 15 Stage 0 (T0a, N0, M0) 16 Stage 0is (Tis, N0, M0) 17 Stage I (T1 N0 M0) 18 Stage II (T2a, N0, M0; T2b, N0, M0) 19 Stage III (T3a, N0, M0; T3b, N0,...
BioPortfolio Limited 99 Surprisingly low use of gemcitabine with oxaliplatin, considering benefits 99 Fluorouracil and gemcitabine do not display synergy 100 No clinical benefit from gemcitabine and cisplatin 101 Oxaliplatin is a close second in France 101 Unexplained high use of cisplatin in Italy 101 CHAPTER 9 CLINICAL TRIAL INVOLVEMENT 103 Neoadjuvant and/or adjuvant drug therapy 103 Low rates of...
BioPortfolio Limited However, Lilly’s Alimta has the potential to replace 5-FU as the core drug for colorectal cancer treatment 11 Key metrics 13 Summary of research/clinical and commercial attractiveness of launched and Phase III drugs for colorectal cancer 15 CHAPTER 2 COLORECTAL CANCER OVERVIEW 22 The colon and rectum 22 Causes of colorectal cancer 23 Risk factors of colorectal cancer 23...
BioPortfolio Limited TABLE OF CONTENTS ABOUT DATAMONITOR HEALTHCARE 2 About the oncology pharmaceutical analysis team 2 CHAPTER 1 KEY FINDINGS 3 Datamonitor insight into the innovative market 3 Key metrics 8 Summary of research/clinical and commercial attractiveness of molecular -targeted treatments in clinical development 11 CHAPTER 2 CANCER OVERVIEW 22 Cancer treatment 24 Cancer epidemiology 25...
BioPortfolio Limited Commercial Insight: Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market TABLE OF CONTENTS About Datamonitor Healthcare 2 CHAPTER 1 EXECUTIVE SUMMARY 3 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 12 Scope 12 Market definition for this report 12 Cytotoxics 13 L1A – Alkylating agents 13 L1B – Antimetabolites 13 L1C – Vinca alkaloids and other plant products...
BioPortfolio Limited Cancer Overview - Numerous Diverse Drugs Approaching Fruition TABLE OF CONTENTS About the Oncology pharmaceutical analysis team 2 Richard Faint – Director of Oncology 2 CHAPTER 1 KEY FINDINGS 3 Datamonitor insight into the oncology market 3 Key metrics 9 Datamonitor pipeline assessment summary 17 CHAPTER 2 CANCER PATIENT POTENTIAL 38 Introduction 38 Definition of cancer 38...
BioPortfolio Limited The Cancer Market Outlook to 2009 Table of Contents The Cancer Market Outlook to 2009 Executive Summary 12 Patient potential 12 Global market analysis 13 Leading players in the cancer market 14 Development of key cancer markets to 2009 15 Chapter 1 Patient potential 19 Summary 19 Introduction 21 Lung cancer 22 Disease description 22 Epidemiology 23 Current treatments 24 NSCLC 24 SCLC...
Approved Products_2004.xls 194 Jul- 02 Aranes p hyperglycosylated erythropoietin Chemotherapy- induced anemia Amgen 195 Jul- 02 X yrem Sodium oxybate oral solution Cataplexy associated with narcolepsy Orphan Medical 196 Au g- 02 Prestara Prasterone Lupus Genelabs 197 Se p- 02 Hepsera Adefovir dipivoxil Chronic Hepatitus B Gilead 198 Nov- 02 Mitoz ytrex Generic mitomycin Disseminated adenocarcinoma of the...
author: Reijer
Approved Products_2004.xls page 5
author: Reijer
Database C C - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products.Erbitux ™ (2096) CAB2 (3278) Caelyx ® (Pegylated Liposomal Doxorubicin Hydrochloride) (2400) Calanolide A (1030)...
Database E E - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
BioWorld International, July 7, 2004 Trying To Open German Biotech Market, Epigenomics Seeks IPO By Douglas Merrill BioWorld International Correspondent MUNICH, Germany … The initial public offering window for biotechnology companies in Germany might have opened.
BioWorld International, July 7, 2004 page 7
